Catabasis Pharmaceuticals Receives $32,400,000 Series B Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=94d95569-f2a9-45e7-b981-907666ce6f10 - Date
11/14/2013 - Company Name
Catabasis Pharmaceuticals - Mailing Address
One Kendall Square Bldg. 1400E Cambridge, MA 02139 - Company Description
At Catabasis we are dedicated to the discovery and development of innovative, effective and safe medicines to treat inflammatory and metabolic diseases. We have assembled a team of highly motivated and experienced scientists who are committed to improving the lives of patients. - Website
http://www.catabasispharma.com - Transaction Type
Venture Equity - Transaction Amount
$32,400,000 - Transaction Round
Series B - Proceeds Purposes
Catabasis plans to use proceeds from this financing to support the development of its lead compound, CAT-2003, a modulator of the lipid synthesis pathway, which is currently in a Phase 2 clinical trial in patients with hypertriglyceridemia and in combination with statins in patients with hypercholesterolemia. Catabasis also plans to use the proceeds to support the continued clinical and pre-clinical development of other SMART Linker conjugates in the pipeline. - M&A Terms
- Venture Investor
Lightstone Ventures - Venture Investor
SV Life Sciences - Venture Investor
Clarus Ventures - Venture Investor
MedImmune Ventures - Venture Investor
Advanced Technology Ventures
